1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68: 394–424.
2.Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2015; 520: 697–701.
3.Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061–8.
4.Sopik V, Phelan C, Cybulski C, Narod SA. BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clinical genetics. 2015; 87: 411–8.
5.Ried T, Meijer GA, Harrison DJ, Grech G, Franch-Exposito S, Briffa R, et al. The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome. Molecular aspects of medicine. 2019.
6.Tse JWT, Jenkins LJ, Chionh F, Mariadason JM. Aberrant DNA Methylation in Colorectal Cancer: What Should We Target? Trends in cancer. 2017; 3: 698–712.
7.Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature communications. 2013; 4: 2612.
8.Winslow S, Lindquist KE, Edsjo A, Larsson C. The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer. BMC cancer. 2016; 16: 841.
9.Guo S, Deng CX. Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation. International journal of biological sciences. 2018; 14: 2083–93.
10.Liu W, Ye H, Liu YF, Xu CQ, Zhong YX, Tian T, et al. Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer. Oncology letters. 2018; 15: 4351–7.
11.Jia D, Li S, Li D, Xue H, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging. 2018; 10: 592–605.
12.Lin CY, Kwon H, Rangel Rivera GO, Li X, Chung D, Li Z. Sex Differences in Using Systemic Inflammatory Markers to Prognosticate Patients with Head and Neck Squamous Cell Carcinoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2018; 27: 1176–85.
13.Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary oncology (Poznan, Poland). 2015; 19: A68–77.
14.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research. 2015; 43: e47.
15.Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic acids research. 2015; 43: D447–52.
16.Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003; 13: 2498–504.
17.Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC bioinformatics. 2003; 4: 2.
18.Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009; 4: 44–57.
19.Bollschweiler E. Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery. Langenbeck’s archives of surgery. 2003; 388: 239–44.
20.Gao YJ, Liu L, Li S, Yuan GF, Li L, Zhu HY, et al. Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition. OncoTargets and therapy. 2018; 11: 7333–43.
21.Zeng YJ, Lai W, Wu H, Liu L, Xu HY, Wang J, et al. Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer. Oncotarget. 2016; 7: 27394–407.
22.Rupertus K, Sinistra J, Scheuer C, Nickels RM, Schilling MK, Menger MD, et al. Interaction of the chemokines I-TAC (CXCL11) and SDF–1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clinical & experimental metastasis. 2014; 31: 447–59.
23.Liu W, Li L, Ye H, Tao H, He H. Role of COL6A3 in colorectal cancer. Oncology reports. 2018; 39: 2527–36.
24.Ji Q, Wang W, Luo Y, Cai F, Lu Y, Deng W, et al. Characteristic proteins in the plasma of postoperative colorectal and liver cancer patients with Yin deficiency of liver-kidney syndrome. Oncotarget. 2017; 8: 103223–35.
25.Kocsis J, Meszaros T, Madaras B, Toth EK, Kamondi S, Gal P, et al. High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell stress & chaperones. 2011; 16: 49–55.
26.Xiao YC, Yang ZB, Cheng XS, Fang XB, Shen T, Xia CF, et al. CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer letters. 2015; 361: 22–32.
27.Li B, Wang F, Ma C, Hao T, Geng L, Jiang H. Predictive value of IL–18 and IL–10 in the prognosis of patients with colorectal cancer. Oncology letters. 2019; 18: 713–9.
28.Yi W, Xiao E, Ding R, Luo P, Yang Y. High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-kappaB/p53-apoptosis signaling pathway in colorectal cancer. Oncology reports. 2016; 36: 3145–53.
29.Silver DJ, Sinyuk M, Vogelbaum MA, Ahluwalia MS, Lathia JD. The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro-oncology. 2016; 18: 153–9.
30.Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO reports. 2014; 15: 1243–53.
31.Kass L, Erler JT, Dembo M, Weaver VM. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. The international journal of biochemistry & cell biology. 2007; 39: 1987–94.
32.Peranzoni E, Rivas-Caicedo A, Bougherara H, Salmon H, Donnadieu E. Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cellular and molecular life sciences: CMLS. 2013; 70: 4431–48.
33.Reeh KA, Cardenas KT, Bain VE, Liu Z, Laurent M, Manley NR, et al. Ectopic TBX1 suppresses thymic epithelial cell differentiation and proliferation during thymus organogenesis. Development (Cambridge, England). 2014; 141: 2950–8.
34.Wang N, Li Y, Wei J, Pu J, Liu R, Yang Q, et al. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways. Thyroid: official journal of the American Thyroid Association. 2019; 29: 378–94.
35.Zhao Z, Zhang KN, Chai RC, Wang KY, Huang RY, Li GZ, et al. ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme. Disease markers. 2019; 2019: 1802620.
36.Lei Y, Henderson BR, Emmanuel C, Harnett PR, deFazio A. Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. Oncogene. 2015; 34: 485–95.
37.Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014; 513: 382–7.
38.Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, et al. Prognostic impact of programed cell death–1 (PD–1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Molecular cancer. 2016; 15: 55.
39.Barker N, Clevers H. Tumor environment: a potent driving force in colorectal cancer? Trends in molecular medicine. 2001; 7: 535–7.